<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tblu4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">ANOVA; all groups at day 11 time point</th></tr><tr><th>F (1,20) (interaction)</th><th>&#951;<sub>P</sub><sup>2</sup></th><th>Effect size <italic>f</italic></th><th>Power</th><th>Total sample size across all groups</th></tr></thead><tbody><tr><td>3.639500</td><td>0.153959</td><td>0.4265862</td><td>82.39%</td><td>48</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Glass' delta<xref ref-type="table-fn" rid="tblfn1">*</xref></th><th>&#945;</th><th>A priori power</th><th>Sample size group 1</th><th>Sample size group 2</th></tr></thead><tbody><tr><td colspan="7">Bonferroni corrected Welch's <italic>t</italic>-tests</td></tr><tr><td>PBS-treated A549 at day 11</td><td>Cimetidine-treated A549 at day 11</td><td>1.71429</td><td>0.0167</td><td>80.50%</td><td>11<xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td>11<xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td></tr><tr><td colspan="7">Additional comparisons outside the ANOVA framework</td></tr><tr><td>PBS-treated A549 at day 11</td><td>Doxorubicin-treated A549 at day 11</td><td>2.39286</td><td>0.0167</td><td>88.29%</td><td>4<xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td>4<xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>*</label><p>The PBS control group SD was used as the divisor.</p></fn><fn id="tblfn2"><label>&#8224;</label><p>With a sample size of 12 per group derived from the ANOVA, achieved power will be at least 84.36%.</p></fn></table-wrap-foot></table-wrap>